000 03471naa a22005537i 4500
001 UMUN-OA-20261005-MLS-056
003 local
005 20261005174905.0
006 m o d
007 cr||||||||||||
008 261005s2022 xx o u000 0 eng d
024 7 _a10.3389/fimmu.2022.927153
_2doi
035 _a(local)EuropePMC:PMC9226391
040 _alocal
_beng
_clocal
041 0 _aeng
100 0 _aXiaomin Zhang
_eauthor.
245 1 0 _aCAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. /
_cXiaomin Zhang; Lingling Zhu; Hui Zhang [and others].
264 1 _a[Place of publication not identified] :
_bFrontiers Media SA,
_c2022.
300 _a1 online resource (1 article).
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
500 _aPublication type: Review article.
500 _aLinked open-access copy: published version.
506 0 _aOpen access; no subscription required for the linked open-access version.
_fUnrestricted online access
_2star
520 3 _aChimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer treatment, and it has achieved unprecedented success in hematological malignancies, especially in relapsed/refractory (R/R) B cell malignancies. At present, CD19 and BCMA are the most common targets in CAR-T cell therapy, and numerous novel therapeutic targets are being explored. However, the adverse events related to CAR-T cell therapy might be serious or even life-threatening, such as cytokine release syndrome (CRS), CAR-T-cell-related encephalopathy syndrome (CRES), infections, cytopenia, and CRS-related coagulopathy. In addition, due to antigen escape, the limited CAR-T cell persistence, and immunosuppressive tumor microenvironment, a considerable proportion of patients relapse after CAR-T cell therapy. Thus, in this review, we focus on the progress and challenges of CAR-T cell therapy in hematological malignancies, such as attractive therapeutic targets, CAR-T related toxicities, and resistance to CAR-T cell therapy, and provide some practical recommendations.
540 _aCreative Commons Attribution (licence family recorded by the source; version not supplied in metadata).
_uhttps://europepmc.org/articles/PMC9226391
546 _aIn English.
588 0 _aDescription generated from Europe PMC bibliographic metadata retrieved on 5 October 2026; full text linked from the source.
590 _aCourse allocation: B. Sc. Medical Laboratory Science.
650 4 _aHematological malignancies
650 4 _aCombinatorial Therapy
650 4 _aAntigen Escape
650 4 _aImmunosuppressive Tumor Microenvironment
650 4 _aCar-t Cell
650 4 _aCar-t Related Toxicities
653 _aB. Sc. Medical Laboratory Science
653 _aUMUN open access collection
653 _ahematology
655 4 _aReview articles.
700 0 _aLingling Zhu
_eauthor.
700 0 _aHui Zhang
_eauthor.
700 0 _aShanshan Chen
_eauthor.
700 0 _aYang Xiao
_eauthor.
773 0 _tFrontiers in immunology
_gVol. 13, (2022), pages/article 927153
_x1664-3224
856 4 0 _uhttps://europepmc.org/articles/PMC9226391
_yRead open-access publication
_zOpen access.
_70
884 _aCourse selection and automated MARC21 enrichment from Europe PMC metadata.
_g20261005
_khttps://europepmc.org/articles/PMC9226391
_qlocal
942 _n0
999 _c1198
_d1198